文献速递青光眼

青光眼进展短期评估模型在临床实践中的效用估计

Estimated Utility of the Short-term Assessment of Glaucoma Progression Model in Clinical Practice.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

该队列研究基于加州大学圣地亚哥分校青光眼诊断创新研究,纳入97例轻、中、重度开角型青光眼患者,每3个月随访2年。结果显示视野24-2 MD斜率为-0.32 dB/y(95%CI,-0.43至-0.21 dB/y),RNFL厚度斜率为-0.54 μm/y(95%CI,-0.75至-0.32 μm/y);以变化速率为终点、增加检测频率时,18个月至2年随访、少于300例受试者即可达到80%检验效能。

要点

  • 以进展速率为终点并增加检测频率,可将青光眼治疗试验缩短至18个月。
  • 上述设计下检测组间变化速率差异所需总样本量少于300例。
  • 2年随访中视野MD斜率为-0.32 dB/y,RNFL厚度斜率为-0.54 μm/y。

核心结论

  • 以进展速率为终点、频繁检测并获得中等效应量时,青光眼治疗疗效试验可在18个月随访内、少于300例受试者中完成。

研究设计与样本

  • 队列研究,纳入加州大学圣地亚哥分校青光眼诊断创新研究中的轻、中、重度开角型青光眼患者,2012年5月开始入组并随访2年。

主要发现

  • 共97例患者,平均(SD)年龄69(11.4)岁,女性50例(51.5%)。
  • 2年随访中视野24-2 MD斜率均值为-0.32 dB/y(95%CI,-0.43至-0.21 dB/y)。
  • 2年随访中RNFL厚度斜率均值为-0.54 μm/y(95%CI,-0.75至-0.32 μm/y)。

关键数值与推荐

  • 两种结局变化速率检测相似组间差异达到80%检验效能,需总随访18个月至2年且总受试者少于300例。

临床怎么用

  • 结果提示可通过缩短随访时间、增加检测频率并以变化速率为终点来设计青光眼治疗临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinical trials of glaucoma therapies focused on protecting the optic nerve have required large sample sizes and lengthy follow-up to detect clinically relevant change due to its slow rate of progression. Whether shorter trials may be possible with more frequent testing and use of rate of change as the end point warrants further investigation. OBJECTIVE: To describe the design for the Short-term Assessment of Glaucoma Progression (STAGE) model and provide guidance on sample size and power calculations for shorter clinical trials. DESIGN, SETTING, AND PARTICIPANTS: A cohort study of patients with mild, moderate, or advanced open-angle glaucoma recruited from the Diagnostic Innovations in Glaucoma Study at the University of California, San Diego. Enrollment began in May 2012 with follow-up for every 3 months for 2 years after baseline examination. Follow-up was concluded in September 2016. Data were analyzed from July 2019 to January 2021. Visual fields (VF) and optic coherence tomography (OCT) scans were obtained at baseline and for 2 years with visits every 3 months. EXPOSURES: Glaucoma was defined as glaucomatous appearing optic discs classified by disc photographs in at least 1 eye and/or repeatable VF damage at baseline. MAIN OUTCOMES AND MEASURES: Longitudinal rates of change in retinal nerve fiber layer (RNFL) thickness and VF mean deviation (MD) are estimated in study designs of varying length and observation frequency. Power calculations as functions of study length, observation frequency, and sample size were performed. RESULTS: In a total referred sample of 97 patients with mild, moderate, or advanced glaucoma (mean [SD] age, 69 [11.4] years; 50 [51.5%] were female; 19 [19.6%]), over the 2-year follow-up, the mean VF 24-2 MD slope was -0.32 dB/y (95% CI, -0.43 to -0.21 dB/y) and the mean RNFL thickness slope was -0.54 μm/y (95% CI, -0.75 to -0.32 μm/y). Sufficient power (80%) to detect similar group differences in the rate of change in both outcomes was attained with total follow-up between 18 months and 2 years and fewer than 300 total participants. CONCLUSIONS AND RELEVANCE: In this cohort study, results from the STAGE model with reduction of the rate of progression as the end point, frequent testing, and a moderate effect size, suggest that clinical trials to test efficacy of glaucoma therapy can be completed within 18 months of follow-up and with fewer than 300 participants.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Proudfoot JA, Zangwill LM, Moghimi S, et al. Estimated Utility of the Short-term Assessment of Glaucoma Progression Model in Clinical Practice. JAMA Ophthalmol. 2021. PMID: 34110362. doi:10.1001/jamaophthalmol.2021.1812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。